Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Liabilities (2016 - 2025)

Abeona Therapeutics has reported Total Liabilities over the past 15 years, most recently at $60.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $60.4 million for Q4 2025, down 7.0% from a year ago — trailing twelve months through Dec 2025 was $60.4 million (down 7.0% YoY), and the annual figure for FY2025 was $60.4 million, down 7.0%.
  • Total Liabilities for Q4 2025 was $60.4 million at Abeona Therapeutics, up from $59.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for ABEO hit a ceiling of $83.7 million in Q1 2024 and a floor of $23.3 million in Q3 2022.
  • Median Total Liabilities over the past 5 years was $46.8 million (2021), compared with a mean of $49.8 million.
  • Biggest five-year swings in Total Liabilities: crashed 49.56% in 2022 and later soared 141.9% in 2024.
  • Abeona Therapeutics' Total Liabilities stood at $37.2 million in 2021, then increased by 0.63% to $37.5 million in 2022, then skyrocketed by 31.3% to $49.2 million in 2023, then surged by 31.97% to $64.9 million in 2024, then decreased by 7.0% to $60.4 million in 2025.
  • The last three reported values for Total Liabilities were $60.4 million (Q4 2025), $59.9 million (Q3 2025), and $82.7 million (Q2 2025) per Business Quant data.